Researchers at the University of Texas Medical Branch at Galveston found hydrogen sulfide reduces the severity of respiratory syncytial virus, or RSV.
In a study published in the Journal of Virology, researchers used a drug to produce a steady release of hydrogen sulfide to decrease RSV's severity and inflammation.
"This study shows that H2S can reduce viral replication and pro-inflammatory gene expression, both important components of lung injury in respiratory viral infections," said UTMB’s Antonella Casola, MD, lead author and pediatric infectious diseases expert. "This treatment has the potential to help patients with RSV and can be rapidly translated into novel treatment approaches for viral bronchiolitis and pneumonia."
You can view the abstract to the study here.
More on infection control & quality:
5 parasites that have travelled the world
The health risks of antibacterial soap
Experimental Ebola drug proves effective in animal studies
